Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, Peffault de Latour R. Hillmen P, et al. Among authors: grossi f. N Engl J Med. 2021 Mar 18;384(11):1028-1037. doi: 10.1056/NEJMoa2029073. N Engl J Med. 2021. PMID: 33730455 Clinical Trial.
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
de Latour RP, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro CM, Nishimori H, Ajayi T, Al-Adhami M, Deschatelets P, Francois C, Grossi F, Risitano AM, Hillmen P. de Latour RP, et al. Among authors: grossi f. Lancet Haematol. 2022 Sep;9(9):e648-e659. doi: 10.1016/S2352-3026(22)00210-1. Lancet Haematol. 2022. PMID: 36055332 Clinical Trial.
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM, Pullon HWH, Amine I, Bogdanovic A, Deschatelets P, Francois CG, Ignatova K, Issaragrisil S, Niparuck P, Numbenjapon T, Roman E, Sathar J, Xu R, Al-Adhami M, Tan L, Tse E, Grossi FV. Wong RSM, et al. Ann Hematol. 2022 Sep;101(9):1971-1986. doi: 10.1007/s00277-022-04903-x. Epub 2022 Jul 22. Ann Hematol. 2022. PMID: 35869170 Free PMC article.
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG. Liao DS, et al. Among authors: grossi fv. Ophthalmology. 2020 Feb;127(2):186-195. doi: 10.1016/j.ophtha.2019.07.011. Epub 2019 Jul 16. Ophthalmology. 2020. PMID: 31474439 Free article. Clinical Trial.
On the ethics of facial transplantation research.
Wiggins OP, Barker JH, Martinez S, Vossen M, Maldonado C, Grossi F, Francois C, Cunningham M, Perez-Abadia G, Kon M, Banis JC. Wiggins OP, et al. Among authors: grossi f. Am J Bioeth. 2004 Summer;4(3):1-12. doi: 10.1080/15265160490496507. Am J Bioeth. 2004. PMID: 16192123
Investigation of risk acceptance in facial transplantation.
Barker JH, Furr A, Cunningham M, Grossi F, Vasilic D, Storey B, Wiggins O, Majzoub R, Vossen M, Brouha P, Maldonado C, Reynolds CC, Francois C, Perez-Abadia G, Frank JM, Kon M, Banis JC Jr. Barker JH, et al. Among authors: grossi f. Plast Reconstr Surg. 2006 Sep;118(3):663-70. doi: 10.1097/01.prs.0000233202.98336.8c. Plast Reconstr Surg. 2006. PMID: 16932174
507 results